title: Association of uric acid with progression to preeclampsia and development of adverse conditions in gestational hypertensive pregnancies.
abstract: BACKGROUND
  Preeclampsia is a serious pregnancy complication. Gestational hypertension is a common first clinical presentation of preeclampsia. Little is known about which clinical risk factors are associated with the progression from gestational hypertension to preeclampsia.
  
  
  METHODS
  In a retrospective cohort study of 249 singleton pregnant women with an initial presentation of gestational hypertension in an obstetric hospital, we assessed which routinely available clinical risk factors are associated with the progression to preeclampsia and the development of adverse maternal or infant conditions.
  
  
  RESULTS
  The mean serum uric acid level at the initial presentation of gestational hypertension was significantly higher comparing patients who later progressed to preeclampsia to those who did not (5.06 vs. 4.59 mg/dl, P < 0.01). Lower gestational age and higher serum uric acid level at the initial presentation of gestational hypertension and subsequent need for antihypertensive drug treatment for blood pressure (BP) control were associated with significantly increased risks of progression to preeclampsia, and development of adverse maternal or infant conditions. One standard deviation (s.d.) increase in serum uric acid level was associated with 2.3-fold increased odds of progression to preeclampsia (adjusted odds ratio (aORs) 2.33 (95% confidence interval (CI) 1.45-3.74)), and 1.5-fold increased odds of developing clinically significant adverse maternal or infant conditions (aOR 1.49 (1.03-2.17)) irrespective of the progression to preeclampsia.
  
  
  CONCLUSIONS
  Higher serum uric acid levels at the initial presentation of gestational hypertension may indicate heightened risk of progression to preeclampsia and development of adverse maternal/infant conditions.
authors.affiliation: Department of Obstetrics and Gynecology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Yuquan
authors.initials: Y
authors.lastname: Wu
authors.forename: Xu
authors.initials: X
authors.lastname: Xiong
authors.forename: William D
authors.initials: WD
authors.lastname: Fraser
authors.forename: Zhong-Cheng
authors.initials: ZC
authors.lastname: Luo
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005865:Gestational Age; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000097:blood* / Q000503:physiopathology; D033261:Maternal-Fetal Relations / Q000502:physiology; D011225:Pre-Eclampsia / Q000097:blood* / Q000453:epidemiology* / Q000503:physiopathology; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood* / Q000503:physiopathology; D012372:ROC Curve; D012189:Retrospective Studies; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
chemical_list: D015415:Biomarkers; D014527:Uric Acid